Although there is still a lack of sufficient data addressing the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients treated with pasireotide, the results of SGLT-2 inhibitor administration in patients with diabetes and acromegaly have already been reported (69). This evidence concerns the gene SLC5A2 and acromegaly.